Rockledge, Pennsylvania Clinical Trials

A listing of Rockledge, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

etoposide
cancer treatment
lung cancer
metastasis
measurable disease
Fox Chase Cancer Center
 (1.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

antiandrogen therapy
metastasis
prostate cancer
soft tissue lesion
adenocarcinoma of prostate
Research Site
 (1.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

metastatic hormone refractory prostate cancer
docetaxel
targeted therapy
metastasis
drug test
Fox Chase Cancer Center
 (1.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +17 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

targeted therapy
estrogen receptor-positive breast cancer
endocrine therapy
er-positive breast cancer
metastasis
Investigational Site Number 8400001
 (4.6 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +125 other locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease  

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

bradykinesia
tremor
dopamine
parkinsonism
early parkinson's
Abington Neurological Associates Willow Grove
 (5.1 away)
  • 0 views
  • 28 Jun, 2022
  • +125 other locations
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
 (9.6 away) Contact site
  • 0 views
  • 05 Oct, 2021
  • +301 other locations
Test reports v6.12 (DO NOT VISIT)

Test

Abington Neurological Associates Willow Grove
 (5.1 away) Contact site
  • 0 views
  • 02 Mar, 2026
  • +2 other locations
UPENN Case Test Trial 5 (Do Not Make Any Changes)

UPENN Case Test Trial 5 (Do Not Make Any Changes)

Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
 (9.6 away) Contact site
  • 0 views
  • 24 Apr, 2025
  • 1 location
UPENN Case Test Trial 12 (Do Not Make Any Changes)

UPENN Case Test Trial 12 (Do Not Make Any Changes)

Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
 (9.6 away) Contact site
  • 0 views
  • 24 Apr, 2025
  • 1 location
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …

Thomas Jefferson University Hospital
 (9.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations